Securities & Investment Fraud

Horizon Pharma PLC Securities Class Litigation

Introduction

Securities fraud class action litigation has been filed on behalf of investors in Horizon Pharma PLC (“Horizon” or the “Company”) (Nasdaq: HZNP). If you purchased or otherwise acquired Horizon securities between March 13, 2014 and February 26, 2016, inclusive (the “Class Period”), you may move the court for appointment as lead plaintiff by no later than May 9, 2016.

You may retain Lieff Cabraser Heimann & Bernstein, LLP, or other attorneys, as your counsel in the actions. Recognized by the National Law Journal as one of the nation’s top plaintiffs’ law firms, Lieff Cabraser is committed to safeguarding the rights of investors and upholding the integrity of the market. We have significant experience and a successful track record of representing institutional and individual investors in securities and financial fraud litigation.

Horizon investors may choose to have Lieff Cabraser review their claim by completing the contact form below. You can also call Sharon M. Lee of Lieff Cabraser at 1-800-541-7358 to discuss the litigation.

Background on the Horizon Securities Class Litigation

Horizon is a biopharmaceutical company focused on orphan drug development. Its current business model involves acquiring other drug companies, and then marketing and selling the acquired products using specialty pharmacies called pharmacy benefit managers (“PMBs”), with which it has special relationships. As part of its business model, Horizon drastically increased the price of the drugs it obtained and, as a result, lost its Medicare, Medicaid, and cash business, which it offset through its Prescriptions-Made-Easy (“PME”) plan. Under that plan, doctors can send their patients’ prescriptions through a PMB partnered with Horizon that directly mails the prescription to the patient the next day. If the patient’s insurance rejects the prescription, Horizon would absorb the cost.

The action alleges that the use of PMBs and the Company’s PME plan was not a sustainable business practice and left Horizon vulnerable to regulatory scrutiny.

On September 23, 2015, Express Scripts Holding Co. – the second largest U.S. PMB – publically described Horizon’s price increases as “profiteering.” On this news, Horizon’s stock price dropped $1.90 per share, or 7.4% from a closing price of $25.69 on September 23, 2015, to close at $23.79 per share on September 24, 2015.

On October 19, 2015, The New York Times published an article criticizing Horizon’s business model and PME Program. On this news, the Company’s stock price fell $3.81 per share, or 19.98% from a closing price of $19.07 on October 19, 2015, to close at $15.26 per share on October 20, 2015.

On October 22, 2015, biopharmaceutical Depomed, Inc. issued a statement describing its rejection of an exchange offer from Horizon and detailing: (1) why Horizon’s price increases were not sustainable; (2) how many of Horizon’s drugs had been removed from the largest PMBs; and (3) how the PME Program damaged Horizon’s realized net sales as a percentage of gross sales. On this news, Horizon’s stock price dropped $1.71 per share, or 11.53% from a closing price of $14.83 on October 21, 2015, to close at $13.12 per share on October 22, 2015, on extremely high trading volume.

Finally, on February 29, 2016, Horizon disclosed that it had received a subpoena from the U.S. Attorney’s Office for the Southern District of New York regarding the Company’s use of financial assistance to help patients pay for the Company’s drugs, as well as its sales and marketing activities and relationship with pharmacies. On this news, Horizon’s stock price declined $2.63 per share, or 13.29% from a closing price of $19.79 on February 26, 2016, to close at $17.16 per share on February 29, 2016, on extraordinarily high trading volume.

Shareholder Contact Form

First Name (required)

Last Name (required)

Email address (required)

Street Address

City

State

Zip

Telephone Day

Telephone Eve

How did you find our site?

Are you currently represented by an attorney?

II. TRANSACTIONS IN HORIZON PHARMA SECURITIES

Number of Securities - Horizon Pharma shares held immediately before the start of the Class Period on February 28, 2012:

From February 28, 2012 through October 3, 2016, inclusive, I made the following transactions in Horizon Pharma shares:

PURCHASES

Date
No. of Shares
Price

show more rows

SALES

Date
No. of Shares
Price

show more rows

During the 90 days after October 3, 2016, I made the following transactions in Horizon Pharma shares:

SALES

Date
No. of Shares
Price

show more rows

Comments & questions:

Please sign me up for your Consumer Law newsletter. Yes

Please leave this field empty.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Seattle, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for thirteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Best Lawyers and U.S. News have named Lieff Cabraser as a “Law Firm of the Year” for each year the publications have given this award to law firms.